Zealand Pharma A/S

Total Valuation

Zealand Pharma A/S carries a market capitalization of 2.42B, placing it among publicly traded companies globally. Its enterprise value stands at 5.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Zealand Pharma A/S currently has 69.39M shares outstanding.

Valuation Ratios

Zealand Pharma A/S trades at a trailing price-to-earnings ratio of 7.36. The price-to-sales ratio is 4.34, and the price-to-book ratio stands at 1.10.

Enterprise Valuation

On an enterprise value basis, Zealand Pharma A/S trades at an EV/EBITDA multiple of 2.33 and an EV/FCF ratio of 5.68. The EV/Sales ratio of 1.25 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2.33 provides insight into valuation relative to core operating earnings.

Financial Position

Zealand Pharma A/S maintains a current ratio of 13.98, meaning it holds 14.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.28, indicating elevated leverage, while an interest coverage ratio of 92.44 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Zealand Pharma A/S posts a return on equity of 16.30 and a return on invested capital of 13.78.

Taxes

Over the trailing twelve months, Zealand Pharma A/S has paid 99.11M in income taxes, reflecting an effective tax rate of 3.49.

Stock Price Statistics

Zealand Pharma A/S's stock has declined approximately -52.5419% over the past 52 weeks. The 50-day moving average sits at 44.11, while the 200-day moving average is 48.76.

Income Statement

Over the trailing twelve months, Zealand Pharma A/S generated 4.64B in revenue and converted that into 2.74B in net income, yielding earnings per share of 38.83. EBITDA reached 2.50B, while operating income came in at 2.50B.

Balance Sheet

Zealand Pharma A/S holds 14.46B in cash and equivalents against 411.00M in total debt, resulting in a net debt position of -3.73B. Total book value stands at 18.00B, with working capital of 17.35B providing operational flexibility.

Cash Flow

Zealand Pharma A/S produced -1.75B in operating cash flow over the past twelve months. After subtracting -78.07M in capital expenditures, free cash flow totaled -1.83B - equivalent to -26.00 per share.

Margins

Zealand Pharma A/S operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 53.88 and net profit margin of 59.00 provide insight into operational efficiency.

Dividends & Yields

Scores

Zealand Pharma A/S posts an Altman Z-Score of 8.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.